AU Stock MarketDetailed Quotes
PTX Prescient Therapeutics Ltd
- 0.042
- +0.001+2.44%
20min DelayMarket Closed Dec 13 14:02 AET
33.82MMarket Cap-4.20P/E (Static)
0.043High0.041Low168.98KVolume0.042Open0.041Pre Close7.05KTurnover0.07252wk High0.03%Turnover Ratio805.32MShares0.03752wk Low-0.01EPS TTM27.87MFloat Cap78409.237Historical HighLossP/E (Static)663.52MShs Float0.022Historical Low-0.01EPS LYR4.88%Amplitude--Dividend TTM1.91P/B1Lot Size--Div YieldTTM
About Prescient Therapeutics Ltd Company
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Company Profile
SymbolPTX
Company NamePrescient Therapeutics Ltd
Founded1986
MarketASX
Employees1
Fiscal Year Ends06-30
AddressLevel 4, 100 Albert Road South Melbourne
CityMelbourne
CountryAustralia
Zip Code3205
Phone+61 396927222
Share RegistryAUTOMIC REGISTRY SERVICES
Level 5, 126 Phillip Street, SYDNEY, NSW, AUSTRALIA, 2000
02 9698 5414
Company Executives
- Name
- Position
- Salary
- Steven Yatomi-Clarke
- Chief Executive Officer,Managing Director
- --
- Steven (Steve) Barnard Engle
- Non-Executive Chairman,Non-Executive Director
- --
- James Campbell
- Non-Executive Director
- --
- Ellen Gwen Feigal
- Non-Executive Director
- --
- Allen James Ebens
- Non-Executive Director
- --
Heat List
AU
Overall
Symbol
Price
% Chg
No Data